Chemed Corp. (CHE)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$519.84-0.88%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · CHE
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 7 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $520 CHE trades at 23× p/e, below its 23× p/e peer median, but our blended $458 fair value sits below the price. It's a high-confidence read. Even valued only for durable growth at sustainable margins, it's worth about $561 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| graham number | 12M | $179.90 | — | — | TTM | high |
| Peer EV/EBITDA | 12M | $389.47 | 12.7 | 30.50 | TTM | high |
| Peer P/E | 12M | $523.79 | 22.9 | 22.86 | TTM | high |
| Peer P/S | 12M | $746.68 | 3.8 | 196.61 | TTM | high |
| residual income |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 8673% over what the business is worth with no growth; closing that gap needs roughly 295.8 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $0.28/sh owner earnings.
Roughly priced in line with peers.
Around its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $137.00 |
| — |
| — |
| TTM |
| high |
| Own P/E history | 12M | $531.95 | 23.3 | 22.86 | TTM | high |
| triangulated | 12M | $544.42 | 22.9 | 23.76 | Triangulated | high |
| Peer P/E | 3Y | $709.95 | 22.9 | 30.98 | Hist. CAGR(prov.) | medium |
| Peer P/S | 3Y | $933.69 | 3.8 | 245.85 | guidance | medium |
| Own P/E history | 3Y | $721.01 | 23.3 | 30.98 | Hist. CAGR(prov.) | medium |
| Peer P/E | 5Y | $812.82 | 22.9 | 35.47 | Hist. CAGR(prov.) | high |
| Peer P/S | 5Y | $1068.98 | 3.8 | 281.47 | guidance | high |
| Own P/E history | 5Y | $825.49 | 23.3 | 35.47 | Hist. CAGR(prov.) | high |